A
Alcista
Alcista · 25%LXRX
$2.20
Precio del escenario
$1.560
-0.020 (-1.27%)Al cierre
Loading chart…
- Máximo
- 1.617
- Apertura
- 1.590
- Precio medio ponderado por volumen
- 1.57
- Volumen
- 1.40M
- Capitalización
- 629.00M
- Mínimo
- 1.545
- Importe
- 2.20M
- EV/EBITDA, TTM
- -1.09
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Análisis de IA of Lexicon Pharmaceuticals Inc (LXRX)
MantenerLexicon Pharmaceuticals Inc (LXRX) is currently trading at $1.52, which is significantly below the analyst price target of $8, indicating a potential upside of over 400%. However, the stock has a very low RSI of 19.53, suggesting it is oversold, but it has also experienced a 25.85% decline over the past 20 days, indicating bearish momentum. The main risk is the company's negative earnings trend, with a net income loss of $31.77 million reported in Q2 2026, which raises concerns about its financial stability.
Recomendaciones de analistas (7)
+158.33% de potencial alcista
Comprar
4 Comprar
3 Mantener
0 Vender
Actual: 1.56
Mínimo
2.10
Promedio
4.03
Máximo
6.00
Cantor Fitzgerald
Sobreponderar
$8
2026-09-28
Cantor Fitzgerald
2026-09-28
Precio objetivo
$8
Sobreponderar
Citi
Comprar
—
2026-05-11
Citi
2026-05-11
Precio objetivo
—
Comprar
Citi
Comprar
—
2026-03-10
Citi
2026-03-10
Precio objetivo
—
Comprar
H.C. Wainwright
Comprar
$6
2026-03-05
H.C. Wainwright
2026-03-05
Precio objetivo
$6
Comprar
Citi
Comprar
—
2025-08-07
Citi
2025-08-07
Precio objetivo
—
Comprar
Métricas de valoración
El PER previsto actual de Lexicon Pharmaceuticals Inc (LXRX) es 0.00, frente a su media de 5 años de -3.17.
Escenarios de precio de Alphio AI para LXRX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LXRX en cartera
Cronología de eventos
Noticias
9.010-21NewsfilterSotagliflozin Shows Positive Effects on Cardiac Function in Hypertrophic Cardiomyopathy
6.009-28FoolAnalyst Initiates Bullish Coverage on Lexicon Pharmaceuticals
6.009-28NASDAQ.COMAnalyst Bullish on Lexicon Pharmaceuticals' Prospects
9.008-31NASDAQ.COMLexicon Pharmaceuticals Reports New Sotagliflozin Data from SOLOIST-WHF Trial
- 9.008-31Newsfilter
Lexicon's Drug Shows Efficacy in Heart Failure Patients
Preguntas frecuentes sobre LXRX, respondidas por Alphio AI
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Lexicon Pharmaceuticals Inc (LXRX) is currently trading at $1.52, which is significantly below the analyst price target of $8, indicating a potential upside of over 400%. However, the stock has a very low RSI of 19.53, suggesting it is oversold, but it has also experienced a 25.85% decline over the past 20 days, indicating bearish momentum. The main risk is the company's negative earnings trend, with a net income loss of $31.77 million reported in Q2 2026, which raises concerns about its financial stability.
7 analysts cover LXRX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 4.03.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.